Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP379936.RASYVFFJ4Z7pmEp5zsDJU3kZyWT8vYRO3PWUTe2_olIQE130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379936.RASYVFFJ4Z7pmEp5zsDJU3kZyWT8vYRO3PWUTe2_olIQE130_provenance.
• NP380457.RAW35WxKQ0MFVdwqha54Zfjq5jU404LQCRp0p0t9txULY130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380457.RAW35WxKQ0MFVdwqha54Zfjq5jU404LQCRp0p0t9txULY130_provenance.
• NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351412.RADpGojIQOhf4i-bLdHkhzWPqCKQE1-G55nMSk-E9ZZGY130_provenance.
• NP351415.RAXez6rVnNuukUDquAr_rjid7yfeuuz_XR61c7SKPhemA130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351415.RAXez6rVnNuukUDquAr_rjid7yfeuuz_XR61c7SKPhemA130_provenance.
• NP380568.RAoIwrakc7HQ-tIEnnHuGrQ2GMxO7B_XmvHkSXNgIWdQ4130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380568.RAoIwrakc7HQ-tIEnnHuGrQ2GMxO7B_XmvHkSXNgIWdQ4130_provenance.
• NP351416.RAsPMhtG9FYlSgaK5eAymCk0SqNKmPCvbEsYR6ZccH8I8130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351416.RAsPMhtG9FYlSgaK5eAymCk0SqNKmPCvbEsYR6ZccH8I8130_provenance.
• NP379530.RAFgnLOsLyUKuIbaom03W3qc3MJlMwWJeFQfEsOSwtZlc130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379530.RAFgnLOsLyUKuIbaom03W3qc3MJlMwWJeFQfEsOSwtZlc130_provenance.
• NP351414.RAxoIXN8LBSPBanEDdkE4YafcMKY_JUP6D9dY1vDOKfws130_assertion description "[Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, and 8 StD or PD for patients without amplification (P = 0.008).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP351414.RAxoIXN8LBSPBanEDdkE4YafcMKY_JUP6D9dY1vDOKfws130_provenance.